sumamed suukaudse suspensiooni pulber
teva pharma b.v. - asitromütsiin - suukaudse suspensiooni pulber - 20mg 1ml 20ml 1tk
sumamed forte suukaudse suspensiooni pulber
teva pharma b.v. - asitromütsiin - suukaudse suspensiooni pulber - 40mg 1ml 30ml 1tk; 40mg 1ml 15ml 1tk
propra-ratiopharm 40 mg õhukese polümeerikattega tablett
ratiopharm gmbh - propranolool - õhukese polümeerikattega tablett - 40mg 50tk; 40mg 100tk
azithromycin sandoz 500mg õhukese polümeerikattega tablett
sandoz gmbh - asitromütsiin - õhukese polümeerikattega tablett - 500mg 12tk; 500mg 50tk; 500mg 3tk; 500mg 30tk
sumamed õhukese polümeerikattega tablett
teva pharma b.v. - asitromütsiin - õhukese polümeerikattega tablett - 500mg 3tk
mirador® 250 sc
adama - suspensioonikontsentraat - asoksüstrobiin - fungitsiidid
ultomiris
alexion europe sas - ravulizumab - hemoglobinuuria, paroksüsmaalne - selektiivsed immunosupressandid - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
midazolam accord 5mg/ml süste-/infusioonilahus
accord healthcare b.v. - midasolaam - süste-/infusioonilahus - 5mg 1ml 1ml 10tk; 5mg 1ml 3ml 10tk; 5mg 1ml 10ml 10tk; 5mg 1ml 10ml 1tk
lekoklar xl 500 mg toimeainet modifitseeritult vabastav tablett
sandoz pharmaceuticals d.d. - klaritromütsiin - toimeainet modifitseeritult vabastav tablett - 500mg 7tk; 500mg 10tk; 500mg 5tk; 500mg 14tk
solu-cortef süstelahuse pulber ja lahusti
pfizer europe ma eeig - hüdrokortisoon - süstelahuse pulber ja lahusti - 100mg 1tk